TENOFOVIR (TFV) ALAFENAMIDE (TAF) DOSE IN THE FIRST PIBASED SINGLE TABLET REGIMEN (STR) DARUNAVIR/COBICISTAT/EMTRICITABINE/TAF (DRV/COBI/FTC/TAF; D/C/F/TAF).

Custodio J. M.; Wei X.; Wang H.; Hepner M.; Zack J. Z.; Callebaut C.; McCallister S.; Miller M.; Kearney B. P.; Ramanathan S.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >TENOFOVIR (TFV) ALAFENAMIDE (TAF) DOSE IN THE FIRST PIBASED SINGLE TABLET REGIMEN (STR) DARUNAVIR/COBICISTAT/EMTRICITABINE/TAF (DRV/COBI/FTC/TAF; D/C/F/TAF).

【24h】

TENOFOVIR (TFV) ALAFENAMIDE (TAF) DOSE IN THE FIRST PIBASED SINGLE TABLET REGIMEN (STR) DARUNAVIR/COBICISTAT/EMTRICITABINE/TAF (DRV/COBI/FTC/TAF; D/C/F/TAF).

机译：替诺福韦（TFV）阿拉法酰胺（TAF）剂量在第一批基于PI的单片片剂（STR）达鲁纳韦/可比西他特/依他西他滨/ TAF（DRV / COBI / FTC / TAF; D / C / F / TAF）中。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2015年第s1期|共1页
作者
Custodio J. M.; Wei X.; Wang H.; Hepner M.; Zack J. Z.; Callebaut C.; McCallister S.; Miller M.; Kearney B. P.; Ramanathan S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
专利

1. TENOFOVIR (TFV) ALAFENAMIDE (TAF) DOSE IN THE FIRST PIBASED SINGLE TABLET REGIMEN (STR) DARUNAVIR/COBICISTAT/EMTRICITABINE/TAF (DRV/COBI/FTC/TAF; D/C/F/TAF). [J] . Custodio J. M., Wei X., Wang H., Clinical Pharmacology and Therapeutics . 2015,第S1期

机译：替诺福韦（TFV）阿拉法酰胺（TAF）剂量在第一批基于PI的单片片剂（STR）达鲁纳韦/可比西他特/依他西他滨/ TAF（DRV / COBI / FTC / TAF; D / C / F / TAF）中。
2. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [J] . Eron Joseph J., Orkin Chloe, Cunningham Douglas, Antiviral Research . 2019,第期

机译：第9周的疗效和安全结果3阶段，随机祖母绿试验评估从增强蛋白酶抑制剂的切换加上Emtricitabine / Tenofovir Disoproxil富马酸莫霉素治疗达伦韦/钴/ Emtricitabine / Tenofovir Alafenaine的单片体方案（D / C / F / TAF）在治疗经验丰富的病毒学 - 被抑制的成年人与HIV-1一起生活
3. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials [J] . Lathouwers Erkki, Wong Eric Y., Brown Kimberley, AIDS Research and Human Retroviruses . 2020,第1期

机译：每日48周的抗性分析曾经，单片机中达伦韦/诺福尼亚州/替斯塔布胺/替诺维尔（D / C / F / TAF）与HIV-1的成人中，III期随机琥珀和祖母绿试验
4. Week 48 Results of EMERALD: A Phase 3 Randomized Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD) Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：EMERALD的第48周结果：第3阶段的非劣效性研究评估了从加强蛋白酶抑制剂（bPI）加恩曲他滨（FTC）/替诺福韦富马酸替诺福韦酯（TDF）转换为每日一次（QD）的功效和安全性）在病毒学上被抑制感染了HIV-1的成年人中Darunavir / Cobicistat / Emtricitabine / Tenofovir Alafenamide（D / C / F / TAF）的单片治疗方案（STR）
5. Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：每周48个祖母绿的结果：第3期，随机的非劣升性研究，评估从增强蛋白酶抑制剂（BPI）加上的促蛋白（BPI）和替尼罗韦（FTC）/ Tenofovir Disoproxil umarate（TDF）方案的疗效和安全性对一次每日（QD ），在病毒学抑制的单片机/ Cobicistat / Emtricisabine / enftricitabine / Tenofovir Alafenainide（D / C / F / TAF）的单片植物（str），HIV-1感染的成年人

TENOFOVIR (TFV) ALAFENAMIDE (TAF) DOSE IN THE FIRST PIBASED SINGLE TABLET REGIMEN (STR) DARUNAVIR/COBICISTAT/EMTRICITABINE/TAF (DRV/COBI/FTC/TAF; D/C/F/TAF).

著录项

相似文献

相关主题

期刊订阅